CA2961913A1 - Pichinde virus reverse genetics system and methods of use - Google Patents
Pichinde virus reverse genetics system and methods of use Download PDFInfo
- Publication number
- CA2961913A1 CA2961913A1 CA2961913A CA2961913A CA2961913A1 CA 2961913 A1 CA2961913 A1 CA 2961913A1 CA 2961913 A CA2961913 A CA 2961913A CA 2961913 A CA2961913 A CA 2961913A CA 2961913 A1 CA2961913 A1 CA 2961913A1
- Authority
- CA
- Canada
- Prior art keywords
- protein
- virus
- genomic segment
- coding region
- genomic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10041—Use of virus, viral particle or viral elements as a vector
- C12N2760/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462053443P | 2014-09-22 | 2014-09-22 | |
| US62/053,443 | 2014-09-22 | ||
| PCT/US2015/051337 WO2016048949A1 (en) | 2014-09-22 | 2015-09-22 | Pichinde virus reverse genetics system and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2961913A1 true CA2961913A1 (en) | 2016-03-31 |
Family
ID=54238628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2961913A Pending CA2961913A1 (en) | 2014-09-22 | 2015-09-22 | Pichinde virus reverse genetics system and methods of use |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10533159B2 (https=) |
| EP (1) | EP3198008B1 (https=) |
| JP (1) | JP6875274B6 (https=) |
| KR (1) | KR20170057384A (https=) |
| CN (1) | CN107109371A (https=) |
| AU (1) | AU2015321557B2 (https=) |
| BR (1) | BR112017005744B1 (https=) |
| CA (1) | CA2961913A1 (https=) |
| ES (1) | ES2746150T3 (https=) |
| MX (1) | MX391006B (https=) |
| PL (1) | PL3198008T3 (https=) |
| WO (1) | WO2016048949A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107109371A (zh) | 2014-09-22 | 2017-08-29 | 明尼苏达大学评议会 | 皮钦德病毒反向遗传学系统及其使用方法 |
| SI3218504T1 (sl) * | 2014-11-13 | 2020-11-30 | Universite De Geneve | Tri-segmentirani arenavirusi kot vakcinski vektorji |
| AU2016274655B2 (en) | 2015-06-10 | 2021-06-17 | NeoTrail Therapeutics, Inc. | HPV vaccines |
| CA3003557A1 (en) | 2015-11-04 | 2017-05-11 | Hookipa Biotech Ag | Vaccines against hepatitis b virus |
| DK3373959T3 (da) | 2015-11-12 | 2022-09-19 | Hookipa Biotech Gmbh | Arenaviruspartikler som cancervacciner |
| IL262963B2 (en) * | 2016-05-18 | 2025-01-01 | Hookipa Biotech Gmbh | Trisegmented PICHINDE viruses as vaccine vectors |
| US20230310574A1 (en) * | 2020-08-06 | 2023-10-05 | Regents Of The University Of Minnesota | Multivalent vaccines against turkey arthritis reovirus |
| WO2022269362A2 (en) | 2021-06-21 | 2022-12-29 | Vaxxinova International B.V. | Veterinary viral vector |
| WO2024155646A1 (en) * | 2023-01-17 | 2024-07-25 | Regents Of The University Of Minnesota | Multivalent vaccines against tuberculosis |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2170622B1 (es) | 1999-12-03 | 2004-05-16 | Consejo Superior De Investigaciones Cientificas | Clones y vectores infectivos derivados de coronavirus y sus aplicaciones. |
| ES2424214T3 (es) | 2007-08-27 | 2013-09-30 | Siga Technologies, Inc. | Medicamentos antivirales para el tratamiento de una infección por Arenavirus |
| AP3126A (en) | 2007-12-21 | 2015-02-28 | Government Of The Us Secretary | Recombinant rift valley fever (RVF) viruses and methods of use |
| SI2604695T1 (sl) * | 2007-12-27 | 2023-03-31 | Universitaet Zuerich Prorektorat Forschung | Replikacijsko defektni arenavirusni vektorji |
| EP2478103A4 (en) | 2009-09-16 | 2014-02-19 | Univ Tulane | LASSAVIRUS-like PARTICLES AND METHOD FOR THE PRODUCTION THEREOF |
| GB201007790D0 (en) | 2010-05-10 | 2010-06-23 | Isis Innovation | Compositions |
| JP2013531496A (ja) | 2010-06-06 | 2013-08-08 | モウント シナイ スクール オフ メディシネ | 組換えｒｎａウイルス及びその使用 |
| CN107109371A (zh) | 2014-09-22 | 2017-08-29 | 明尼苏达大学评议会 | 皮钦德病毒反向遗传学系统及其使用方法 |
-
2015
- 2015-09-22 CN CN201580063072.3A patent/CN107109371A/zh active Pending
- 2015-09-22 EP EP15772173.9A patent/EP3198008B1/en active Active
- 2015-09-22 BR BR112017005744-1A patent/BR112017005744B1/pt active IP Right Grant
- 2015-09-22 PL PL15772173T patent/PL3198008T3/pl unknown
- 2015-09-22 AU AU2015321557A patent/AU2015321557B2/en active Active
- 2015-09-22 CA CA2961913A patent/CA2961913A1/en active Pending
- 2015-09-22 JP JP2017515764A patent/JP6875274B6/ja active Active
- 2015-09-22 US US15/513,045 patent/US10533159B2/en active Active
- 2015-09-22 MX MX2017003694A patent/MX391006B/es unknown
- 2015-09-22 KR KR1020177010589A patent/KR20170057384A/ko not_active Withdrawn
- 2015-09-22 WO PCT/US2015/051337 patent/WO2016048949A1/en not_active Ceased
- 2015-09-22 ES ES15772173T patent/ES2746150T3/es active Active
-
2019
- 2019-12-10 US US16/708,825 patent/US11993789B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20170057384A (ko) | 2017-05-24 |
| PL3198008T3 (pl) | 2020-03-31 |
| EP3198008B1 (en) | 2019-05-29 |
| ES2746150T3 (es) | 2020-03-04 |
| WO2016048949A1 (en) | 2016-03-31 |
| BR112017005744B1 (pt) | 2023-11-28 |
| US11993789B2 (en) | 2024-05-28 |
| BR112017005744A2 (pt) | 2017-12-12 |
| CN107109371A (zh) | 2017-08-29 |
| US20200165578A1 (en) | 2020-05-28 |
| AU2015321557B2 (en) | 2020-05-14 |
| US20170292119A1 (en) | 2017-10-12 |
| AU2015321557A1 (en) | 2017-04-06 |
| MX391006B (es) | 2025-03-21 |
| JP6875274B2 (ja) | 2021-05-19 |
| EP3198008A1 (en) | 2017-08-02 |
| JP2017529084A (ja) | 2017-10-05 |
| US10533159B2 (en) | 2020-01-14 |
| MX2017003694A (es) | 2017-10-12 |
| JP6875274B6 (ja) | 2021-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11993789B2 (en) | Pichinde virus reverse genetics systems and methods of use | |
| US12410409B2 (en) | Influenza viruses with mutant PB2 gene segment as live attenuated vaccines | |
| Pena et al. | Influenza viruses with rearranged genomes as live-attenuated vaccines | |
| Kraatz et al. | Deletion mutants of Schmallenberg virus are avirulent and protect from virus challenge | |
| JP2017529084A5 (https=) | ||
| CN103209706B (zh) | 生产布尼亚病毒复制子颗粒的方法 | |
| Sun et al. | Methyltransferase-defective avian metapneumovirus vaccines provide complete protection against challenge with the homologous Colorado strain and the heterologous Minnesota strain | |
| Jang et al. | Principles underlying rational design of live attenuated influenza vaccines | |
| AU2015345579B2 (en) | Live attenuated vaccines for influenza viruses | |
| Bergthaler et al. | Envelope exchange for the generation of live-attenuated arenavirus vaccines | |
| Wang et al. | Genome‐Wide Codon Reprogramming Enables a Multifactorially Attenuated Influenza Vaccine with Broad Cross‐Protection | |
| US20230310574A1 (en) | Multivalent vaccines against turkey arthritis reovirus | |
| US20250082743A1 (en) | Viral vectored vaccines for swine influenza virus and methods of use | |
| US20240285748A1 (en) | Veterinary viral vector | |
| CN110573613A (zh) | 流感b病毒突变体及其用途 | |
| Pérez-Girón et al. | Mucosal poly IC improves protection elicited by replicating influenza vaccines via enhanced dendritic cell function and T cell immunity | |
| Van den Hoecke | Deep sequencing of influenza A viruses tempered by antibodies against the M2 ectodomain | |
| Kawaoka et al. | Reverse Genetics Approaches for Rational Design of Inactivated and Live Attenuated Influenza Vaccines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20200921 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20240805 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD Year of fee payment: 9 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240913 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240913 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240913 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20241030 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250129 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250516 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250516 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 10TH ANNIV.) - STANDARD Year of fee payment: 10 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250915 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250915 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251231 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260108 |